Lecanemab for the Treatment of Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease
in Adults that are Apolipoprotein E ε4 (ApoEε4)
Heterozygotes or Non-Carriers
Perry et al CTAD Presentation
Lecanemab for the Treatment of Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease
in Adults that are Apolipoprotein E ε4 (ApoEε4)
Heterozygotes or Non-Carriers
